document
June 1, 2012 — 00:00
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
373
document
June 1, 2012 — 00:00
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
document
May 3, 2012 — 00:00
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
document
May 3, 2012 — 00:00
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
document
May 3, 2012 — 00:00
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
document
May 3, 2012 — 00:00
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
document
May 2, 2012 — 00:00
A.M. Best has upgraded the Issuer Credit Ratings (ICR) of SCOR SE and its main subsidiaries from “a” to “a+”. They have also affirmed the Financial Strength Ratings of “A” (Excellent).
document
March 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
document
March 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
document
March 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011
document
February 9, 2012 — 00:00
SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.
